Familial Primary Pulmonary Hypertension - 25 Studies Found

Not yet recruiting : ADAPT - A Patient Registry of the Real-world Use of Orenitram®
: Pulmonary Arterial Hypertension
: 2017-02-02
: Drug: Oral treprostinil Sustained-release oral tablets for TID administration
Withdrawn : Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
: Pulmonary Arterial Hypertension
: 2017-01-06
:
  • Drug: Parenteral Remodulin (treprostinil) injection

Not yet recruiting : Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
: Pulmonary Arterial Hypertension
: 2016-12-19
:
  • Drug: Oral Treprostinil Sustai
Completed : Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
: Pulmonary Arterial Hypertension
: 2016-11-14
:
  • Drug: macitentan used in open

Completed : The Effect of Adding Exercise Training to Optimal Therapy in PAH
: Pulmonary Arterial Hypertension
: 2016-11-08
: Other: Exercise therapy 3-week residential phase and 12-we
Completed : Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
: Idiopathic Pulmonary Arterial Hypertension
: 2015-04-23
Withdrawn : FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
: Pulmonary Arterial Hypertension
: 2015-04-06
: Other: CT imaging, functional PET imaging Physiology study using CT and functional PET imaging with 13NN
Not yet recruiting : Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
: Pulmonary Arterial Hypertension (PAH)
: 2016-10-12
: Drug: QCC374
Not yet recruiting : A Study to Find Out Whether the Medicine Macitentan Works in Children With Pulmonary Arterial Hypertension (PAH)
: Pulmonary Arterial Hypertension
: 2016-10-12
:
  • Drug: Macitentan Dispersible t
Not yet recruiting : Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
: Pulmonary Arterial Hypertension (PAH)
: 2016-10-05
:
  • Drug: QCC374 0.015 mg and 0.06
<<< Previous | Next >>>